Photo taken from eFFECTOR Therapeutics/LinkedIn
May 22, 2024, 14:42
eFFECTOR Therapeutics announces the initiation of an investigator-sponsored trial in collaboration with the Dana-Farber Cancer Institute
eFFECTOR Therapeutics shared a post on LinkedIn:
“We are excited to announce the initiation of an investigator-sponsored trial evaluating our lead product candidate in patients with estrogen receptor-positive (ER+) endometrial cancer ovarian cancer, in collaboration with the Dana-Farber Cancer Institute. ”
Source: eFFECTOR Therapeutics/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56
Nov 13, 2024, 15:46
Nov 13, 2024, 15:32
Nov 13, 2024, 15:29
Nov 13, 2024, 15:25